New whooping cough vaccine passes major safety check in thousands of adults
NCT ID NCT06798831
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This large Phase 3 trial is testing the safety of a new recombinant pertussis (whooping cough) vaccine in 2,399 healthy adults aged 18 to 75. Participants receive a single booster dose, and researchers monitor for side effects over 28 days. The goal is to confirm the vaccine is safe and consistent across different manufacturing lots.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Recombinant acellular pertussis (aP) vaccine (Pertagen®)
- What this could lead to
- If successful, this could provide a safer, well-tolerated whooping cough booster for adults, helping reduce spread and protect vulnerable populations.
- What could go wrong
- This is a safety-focused trial, not designed to prove effectiveness. Rare side effects may still emerge, and results may not apply to children or older adults.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERTUSSIS VACCINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chula Clinical Research Center (Chula CRC)
Bangkok, Bangkok, 10330, Thailand
-
Queen Saovabha Memorial Institute, Thai Red Cross Society
Bangkok, Bangkok, 10330, Thailand
-
Thai Red Cross AIDS and Infectious Diseases Research Centre
Bangkok, Bangkok, 10330, Thailand